Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TELO
TELO logo

TELO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.330
Open
1.290
VWAP
1.30
Vol
97.34K
Mkt Cap
45.38M
Low
1.250
Amount
126.54K
EV/EBITDA(TTM)
--
Total Shares
34.38M
EV
38.10M
EV/OCF(TTM)
--
P/S(TTM)
--
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Show More

Events Timeline

(ET)
2026-02-17
08:50:00
Telomir Pharmaceuticals Announces New Data on Triple-Negative Breast Cancer
select
2026-02-05 (ET)
2026-02-05
08:30:00
Telomir Pharmaceuticals Announces Telomir-Zn Cellular Study Results
select
2026-01-05 (ET)
2026-01-05
09:40:00
Telomir Pharmaceuticals Announces Efficacy Study Results for Telomir-1 in Triple-Negative Breast Cancer Models
select
2025-12-18 (ET)
2025-12-18
07:50:00
Telomir Pharmaceuticals Announces Safety Study Results for Telomir-1
select
2025-11-25 (ET)
2025-11-25
08:14:02
Telomir Pharmaceuticals Reveals Latest Preclinical Findings on Telomir-1
select
2025-11-21 (ET)
2025-11-21
07:32:56
Telomir Pharmaceuticals Reveals In Vitro Findings for Telomir-1
select
2025-11-12 (ET)
2025-11-12
08:31:10
Telomir Pharmaceuticals Reveals New Preclinical Findings on Telomir-1
select
2025-10-23 (ET)
2025-10-23
07:40:50
Telomir Reports Data Indicating Telomir-1 Reboots Cancer's 'Kill-and-Clean' Defense Mechanism
select
2025-10-21 (ET)
2025-10-21
07:44:54
Telomir Pharmaceuticals Signs Binding Letter of Intent to Acquire TELI Pharmaceuticals
select

News

Benzinga
3.5
01-06Benzinga
Coinbase CEO Armstrong Invests in NewLimit, Secures $45 Million Funding
  • Company Formation: Coinbase CEO Brian Armstrong's startup NewLimit, founded in 2021, focuses on extending human healthspan by treating age-related diseases, with its latest funding round of $45 million boosting its valuation to $1.62 billion, indicating strong market interest in anti-aging technologies.
  • Funding Context: The rapid follow-up funding just five months after its Series B round demonstrates NewLimit's swift growth and investor confidence in the anti-aging sector, with the new capital expected to lay the groundwork for future clinical studies that could advance its technological capabilities.
  • Intensifying Competition: With OpenAI CEO Sam Altman investing $180 million in Retro Biosciences, the race to develop technologies that extend human lifespan is heating up, reflecting significant market attention and potential economic returns in this burgeoning field.
  • Market Reaction: Despite a downturn in anti-aging research stocks in 2025, NewLimit's successful funding round showcases investor confidence in its long-term potential, which may attract further capital into this emerging market.
NASDAQ.COM
4.5
2025-10-10NASDAQ.COM
Friday's Underperformers: Pharmaceutical, Oil, and Gas Exploration & Production Shares
  • Market Performance: Oil and gas exploration and production shares are down approximately 1.6%, with Venture Global experiencing a significant drop of about 19.6% and Amplify Energy down by about 5.5%.

  • Sector Laggards: The decline in oil and gas stocks is highlighted as part of the broader market trends, alongside other sectors such as pharmaceuticals.

Benzinga
4.5
2025-10-07Benzinga
Stock Market Update: Dow Jones and Nasdaq Futures Decline as Trade Deficit Data Release is Postponed Due to Shutdown—Trilogy Metals, AMD, and Applovin Under Scrutiny
  • U.S. Stock Market Update: U.S. stock futures declined following a mixed performance on Monday, with major indices showing slight decreases. The market is influenced by a deal between Advanced Micro Devices and OpenAI, which boosted AI-related stocks.

  • Government Shutdown Impact: The ongoing government shutdown has delayed the release of U.S. trade deficit data, with President Trump indicating a willingness to collaborate with Democrats on healthcare only after the government reopens.

  • Key Stock Movements: Trilogy Metals surged 180.38% after a White House investment announcement, while Applovin fell 2.56% amid an SEC investigation. Advanced Micro Devices rose 2.57% due to its deal with OpenAI, and Telomir Pharmaceuticals jumped 30.99% following positive study results.

  • Economic Outlook: Analysts predict a strong earnings season for Q3 2025, with expectations of low-teens earnings growth for the S&P 500, driven by AI investments and a resilient economy, despite potential tariff pressures.

NASDAQ.COM
2.0
2025-10-07NASDAQ.COM
TELO, PCSA, RVPH, NMTC, BRTX Experience After-Hours Trading Surge Amid Limited News and Specific Updates
  • Biotech Stock Gains: Small-cap biotech stocks TELO, PCSA, RVPH, NMTC, and BRTX experienced significant after-hours gains driven by speculative trading and company updates, despite the absence of new disclosures.

  • Telomir Pharmaceuticals (TELO): TELO shares surged 43% after-hours, attributed to renewed interest in its in vitro data showcasing Telomir-1's unique targeting capabilities in cancer therapies.

  • Processa Pharmaceuticals (PCSA): PCSA shares rose 32.6% in after-hours trading, continuing a rally from the regular session, with no recent official news or updates from the company.

  • NeuroOne Medical Technologies (NMTC): NMTC shares increased 9.5% after announcing a 163% rise in preliminary product revenue for fiscal year 2025, alongside an upcoming virtual webinar, which sparked investor interest.

Benzinga
4.5
2025-08-28Benzinga
Stock Market Update: Nvidia Weighs on Nasdaq Futures—Attention on Dollar General, Dell, and Best Buy
  • Market Overview: U.S. stock futures showed mixed results following gains from the previous day, with Nvidia Corp. experiencing a decline despite reporting better-than-expected second-quarter results.

  • Nvidia's Performance: Nvidia's stock fell due to lack of guidance on H20 shipments to China and weaker data center revenue, although analysts remain optimistic about its leadership in AI infrastructure.

  • Economic Indicators: The 10-year Treasury bond yield was at 4.23%, with markets anticipating an 87.3% chance of interest rate cuts by the Federal Reserve in September; mortgage applications also saw a slight decline.

  • Stock Movements: Notable stock movements included MongoDB Inc. rising 38% after strong earnings, while Kohl’s Corp. gained 24%. Conversely, CEL-SCI Corp. dropped 30.83% after announcing a public offering.

Benzinga
9.5
2025-08-28Benzinga
Snowflake Shares Surge 14%; Check Out 20 Stocks Making Moves in Premarket Trading
  • Snowflake Inc. Financial Results: Snowflake's shares surged 14.2% in pre-market trading after reporting second-quarter revenue of $1.14 billion and adjusted earnings of 35 cents per share, both exceeding analyst expectations.

  • Other Gainers in Pre-Market Trading: Several stocks saw significant gains, including Erayak Power Solution Group (up 52.5%), Top KingWin Ltd (up 50.5%), and Telomir Pharmaceuticals (up 43.9%).

  • Notable Losers in Pre-Market Trading: CEL-SCI Corporation experienced a sharp decline of 29.8% following a public offering announcement, while The Cooper Companies and Cognition Therapeutics also reported losses of 14.5% and 14.1%, respectively.

  • NVIDIA's Performance: NVIDIA shares fell 2% despite reporting better-than-expected earnings and projecting third-quarter revenue within the consensus estimate range.

Valuation Metrics

The current forward P/E ratio for Telomir Pharmaceuticals Inc (TELO.O) is -4.62, compared to its 5-year average forward P/E of -5.83. For a more detailed relative valuation and DCF analysis to assess Telomir Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.83
Current PE
-4.62
Overvalued PE
1.34
Undervalued PE
-13.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4595.74
Current PS
92.14
Overvalued PS
37578.73
Undervalued PS
-28387.25

Financials

AI Analysis
Annual
Quarterly

Whales Holding TELO

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Telomir Pharmaceuticals Inc (TELO) stock price today?

The current price of TELO is 1.32 USD — it has increased 0

What is Telomir Pharmaceuticals Inc (TELO)'s business?

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

What is the price predicton of TELO Stock?

Wall Street analysts forecast TELO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Telomir Pharmaceuticals Inc (TELO)'s revenue for the last quarter?

Telomir Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Telomir Pharmaceuticals Inc (TELO)'s earnings per share (EPS) for the last quarter?

Telomir Pharmaceuticals Inc. EPS for the last quarter amounts to -0.06 USD, decreased -40.00

How many employees does Telomir Pharmaceuticals Inc (TELO). have?

Telomir Pharmaceuticals Inc (TELO) has 0 emplpoyees as of March 22 2026.

What is Telomir Pharmaceuticals Inc (TELO) market cap?

Today TELO has the market capitalization of 45.38M USD.